A randomized, double-blind, placebo-controlled, dose-escalation study of adefovir dipivoxil, an oral prodrug of adefovir, was conducted in 36 human immunodeficiency virus (HIV)-infected subjects to evaluate its anti-HIV activity, safety, and pharmacokinetics. Subjects received placebo or one of three dosages of adefovir dipivoxil daily for 14 days. Median decreases in serum p24 antigen of 31% (P = .02), 25% (P = .31), and 30% (P = .01) occurred in each drug-treated group, respectively, compared with an increase of 17% in the placebo group. Median decreases in serum HIV RNA of 0.4-0.6 log10 copies/mL occurred in the drug-treated groups (P = .03), compared with no change in the placebo group. Gastrointestinal complaints and reversible liver transaminase elevations were the most frequently noted adverse events. Decreases in serum free carnitine occurred in each drug-treated group during treatment. After 14 days of dosing, adefovir dipivoxil demonstrated anti-HIV activity and was best tolerated at the lowest dosage studied, 125 mg daily.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1086/514057 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical management of hypophosphatemic osteomalacia induced by adefovir and tenofovir: Insights from a case report.
Medicine (Baltimore)
November 2024
Department of Endocrinology, Lishui Central Hospital, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang Province, China.
Article Synopsis
- Hypophosphatemic osteomalacia is a rare condition marked by low phosphate levels, which can occur due to genetic or acquired factors, and a case study discusses its management and prognosis when caused by specific antiviral drugs.
- A 55-year-old man with chronic hepatitis B experienced symptoms like chest pain and fatigue after switching from adefovir to tenofovir, leading to the diagnosis of drug-induced hypophosphatemic osteomalacia.
- Treatment included stopping the problematic drugs, switching to entecavir, and recommending dietary changes and supplements, which resulted in improved phosphate levels and resolution of symptoms.
Unachieved antiviral strategies with acyclic nucleoside phosphonates: Dedicated to the memory of dr. Salvatore "Sam" Joseph Enna.
Biochem Pharmacol
October 2024
Department of Laboratory Medicine, The Second Xiangya Hospital, Central South University, Hunan Clinical Molecular Diagnosis Center, Molecular Diagnostic Technology Hunan Engineering Research Center, Clinical Medical Research Center for Molecular Diagnosis of Infectious Diseases in Hunan Province, Changsha 410011, China. Electronic address:
Many acyclic nucleoside phosphonates such as cidofovir, adefovir dipivoxil, tenofovir disoproxil fumarate, and tenofovir alafenamide have been marketed for the treatment or prophylaxis of infectious diseases. Here, this review highlights potent acyclic nucleoside phosphonates for their potential in the treatment of retrovirus (e.g.
View Article and Find Full Text PDFUnderstanding adefovir pharmacokinetics as a component of a transporter phenotyping cocktail.
Eur J Clin Pharmacol
July 2024
Department I of Pharmacology, Center for Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Gleueler Straße 24, Cologne, 50931, Germany.
Article Synopsis
- Adefovir was studied to understand how it interacts with renal transporters when combined with other drugs, showing a 20% increase in systemic exposure when used together with metformin, sitagliptin, pitavastatin, and digoxin.
- A population pharmacokinetic (popPK) model was used to analyze data from 24 healthy subjects, revealing that adefovir's absorption and bioavailability were significantly higher during combination therapy compared to when it was administered alone.
- The findings indicate that while co-administering drugs mainly influenced adefovir's absorption and conversion, its renal elimination process remained unchanged, suggesting limited drug-drug interactions in this context.
[Role of mitochondrial autophagy and the curative effect of rehmannia glutinosa leaves total glycoside capsules on nucleos(t)ide drug-induced renal injury].
Zhonghua Gan Zang Bing Za Zhi
February 2024
Department of Infection, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China.
To study the curative effect of rehmannia glutinosa leaves total glycoside capsules and the role of mitochondrial autophagy on nucleos(t)ide drug-induced renal injury. Adefovir dipivoxil (ADV) was used to construct a hepatitis B virus (HBV) transgenic mouse model for renal injury. Renal function was measured in each group at one and two weeks of modeling.
View Article and Find Full Text PDFA sporadic occurrence of Fanconi syndrome associated with adefovir dipivoxil (ADV) has been reported, particularly when confirmed by renal biopsy. This study presents the case of a 53-year-old man who had been taking ADV 10 mg daily for 10 years to treat chronic hepatitis B (CHB) and subsequently developed Fanconi syndrome. The clinical manifestations included hypophosphatemic osteomalacia, glucosuria, renal tubular acidosis, low-molecular-weight proteinuria, and renal insufficiency.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!